The ingredient in Isapro is recombinant human type II tumor necrosis factor receptor antibody fusion protein, which is an injectable agent that commonly causes local reactions at the injection site, including causing mild to moderate erythema, itching, pain, and swelling. Injection site reactions usually occur within the first month of starting treatment, and occur less frequently in subsequent treatments, with injection site reactions lasting an average of 3-5 days. Other adverse reactions also include causing headache, dizziness, rash, insomnia, cough, abdominal pain, upper respiratory tract infection, elevated blood pressure, increased percentage of peripheral blood lymphocytes, rhinitis, fever, joint aches, muscle aches, drowsiness, facial swelling, and elevated aminotransferase enzymes, most of which do not need to be treated. Therefore, it is important to observe the reaction to the medication during its use and seek medical attention if there is any discomfort.